Information  X 
Enter a valid email address

Xenova Group plc (XEN)

  Print      Mail a friend

Wednesday 07 April, 2004

Xenova Group plc

Xenova Group plc Lease Agreement

Xenova Signs Lease Agreement with Genzyme

Slough, UK, 7 April 2004 - Xenova Group plc (LSE: XEN; NASDAQ: XNVA)
announced today that it has signed a 10 year agreement with Genzyme
Limited ("Genzyme") leasing to them the vacant space in the 310
Cambridge Science Park site.

Genzyme will establish its first European discovery research facility
on the site this month.  Xenova will continue to occupy part of the
Cambridge site together with its adjacent manufacturing facility.

David Oxlade, Chief Executive Officer said: "We are pleased to
welcome Genzyme as a tenant at our Cambridge facility.  This,
together with the disposal of research premises in Farnham in
December, largely completes the planned reduction in UK facilities
occupation following the acquisition of KS Biomedix Holdings plc in
September 2003.  Genzyme's occupation will substantially reduce our
facilities overheads over the coming years."

Xenova Group plc is a UK-based biopharmaceutical company focused on
the development of novel drugs to treat cancer and addiction with a
secondary focus in immunotherapy.  The Company has a broad pipeline
of products in clinical development, including three cancer
programmes:  its lead product TransMIDTM, for the treatment of
high-grade glioma, is ready to enter Phase III trials, and in
addition has novel DNA targeting agents and XR303 both in Phase I for
cancer indications.  Xenova is also developing two therapeutic
vaccines for cocaine and nicotine addiction, which are in Phase II
and Phase I trials respectively.  Quoted on the London Stock Exchange
(XEN) and on NASDAQ (XNVA), Xenova employs approximately 112 people
throughout its sites in the UK and North America. (Reuters XEN.L;
Bloomberg XEN LN)

Genzyme Corporation is a global biotechnology company dedicated to
making a major positive impact on the lives of people with serious
diseases.  Genzyme's research activities in Cambridge will focus on
antibody technology and its application in renal disease, oncology,
and immune-mediated diseases.

For further information about Xenova and its products please visit
the Xenova website at

For Xenova: Disclaimer to take advantage of the "Safe Harbor"
provisions of the US Private Securities Litigation Reform Act of
1995. This press release contains "forward-looking statements,"
including statements about our ability to integrate acquired
businesses and realize cost savings from integration, and the
discovery, development and commercialization of products. Various
risks may cause Xenova's actual results to differ materially from
those expressed or implied by the forward looking statements,
including: unexpected costs and delays in integrating acquired
businesses into our group, adverse results in our drug discovery and
clinical development programs; failure to obtain patent protection
for our discoveries; commercial limitations imposed by patents owned
or controlled by third parties; our dependence upon strategic
alliance partners to develop and commercialize products and services;
difficulties or delays in obtaining regulatory approvals to market
products and services resulting from our development efforts; the
requirement for substantial funding to conduct research and
development and to expand commercialization activities; and product
initiatives by competitors.  For a further list and description of
the risks and uncertainties we face, see the reports we have filed
with the Securities and Exchange Commission.  We disclaim any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events or


Xenova Group plc
+44 (0)1753 706600
David A Oxlade, Chief Executive Officer
Daniel Abrams, Group Finance Director
Veronica Cefis Sellar, Head of Corporate Communications

UK - Financial Dynamics
+44 (0)20 7831 3113
David Yates
Ben Atwell

US - Trout Group BMC Communications
+1 212 477 9007

Media: Brad Miles, ext 17
Daniel Budwick, ext 14
Investors: Jonathan Fassberg, ext 16
Lee Stern, ext 22